AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Genes & Diseases Article
PDF (2.1 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review Article | Open Access

MicroRNAs and JAK/STAT3 signaling: A new promising therapeutic axis in blood cancers

Mehdi Sajjadi-Dokhta, Talar Ahmad Merza Mohamadb, Heshu Sulaiman Rahmanc,d, Marwah Suliman Maashii, Svetlana Danshinae, Navid Shomalia,f, Saeed Solalia,f, Faroogh Marofia,f, Elham Zeinalzadeha,f, Morteza Akbaria, Ali Adilig, Ramin Aslaminabada, Majid Farshdousti Hagha,f( ), Mostafa Jarahianh( )
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz 5166614766, Iran
Department of Pharmacology, College of Pharmacy, Hawler Medical University, Erbil 44001, Iraq
Department of Physiology, College of Medicine, University of Sulaymaniyah, Sulaymaniyah 46001, Iraq
Department of Medical Laboratory Sciences, Komar University of Science and Technology, Sulaymaniyah 46002, Iraq
Department of Propaedeutics of Dental Diseases, I. M. Sechenov First Moscow State Medical University, Moscow 119991, Russia
Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz 5166614766, Iran
Department of Oncology, Tabriz University of Medical Sciences, Tabriz 5166614766, Iran
German Cancer Research Center (DKFZ), Toxicology and Chemotherapy Unit (G401), Heidelberg 69120, Germany
Stem Cells and Regenerative Medicine Unit at King Fahad Medical Research Centre, Jeddah 21589, Saudi Arabia

Peer review under responsibility of Chongqing Medical University.

Show Author Information

Abstract

Blood disorders include a wide spectrum of blood-associated malignancies resulting from inherited or acquired defects. The ineffectiveness of existing therapies against blood disorders arises from different reasons, one of which is drug resistance, so different types of leukemia may show different responses to treatment. Leukemia occurs for a variety of genetic and acquired reasons, leading to uncontrolled proliferation in one or more cell lines. Regarding the genetic defects, oncogene signal transducer and activator of transcription (STAT) family transcription factor, especially STAT3, play an essential role in hematological disorders onset and progress upon mutations, dysfunction, or hyperactivity. Besides, microRNAs, as biological molecules, has been shown to play a dual role in either tumorigenesis and tumor suppression in various cancers. Besides, a strong association between STAT3 and miRNA has been reported. For example, miRNAs can regulate STAT3 via targeting its upstream mediators such as IL6, IL9, and JAKs or directly binding to the STAT3 gene. On the other hand, STAT3 can regulate miRNAs. In this review study, we aimed to determine the role of either microRNAs and STAT3 along with their effect on one another's activity and function in hematological malignancies.

Keywords

miRNAsSTAT3InterleukinJAKsLeukemia

References

1

Mrózek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev. 2004;18(2):115-136.
Crossref Google Scholar
2

Eisfeld AK, Kohlschmidt J, Mims A, et al. Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years. Leukemia. 2020;34(12):3215-3227.
Crossref Google Scholar
3

Brown AL, Hahn CN, Scott HS. Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA). Blood. 2020;136(1):24-35.
Crossref Google Scholar
4

Ashihara E, Takada T, Maekawa T. Targeting the canonical Wnt/β-catenin pathway in hematological malignancies. Cancer Sci. 2015;106(6):665-671.
Crossref Google Scholar
5

Tasian SK, Teachey DT, Rheingold SR. Targeting the PI3K/mTOR pathway in pediatric hematologic malignancies. Front Oncol. 2014;4:108.
Crossref Google Scholar
6

Ge X, Wang X. Role of Wnt canonical pathway in hematological malignancies. J Hematol Oncol. 2010;3:33.
Crossref Google Scholar
7

Vainchenker W, Constantinescu SN. JAK/STAT signaling in hematological malignancies. Oncogene. 2013;32(21):2601-2613.
Crossref Google Scholar
8

Xin P, Xu X, Deng C, et al. The role of JAK/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol. 2020;80:106210.
Crossref Google Scholar
9

Pencik J, Pham HTT, Schmoellerl J, et al. JAK-STAT signaling in cancer: from cytokines to non-coding genome. Cytokine. 2016;87:26-36.
Crossref Google Scholar
10

Kleppe M, Koche R, Zou L, et al. Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms. Cancer Cell. 2018;33(1):29-43.
Crossref Google Scholar
11

Tolomeo M, Cascio A. The multifaced role of STAT3 in cancer and its implication for anticancer therapy. Int J Mol Sci. 2021;22(2):603.
Crossref Google Scholar
12

Constantinescu SN, Girardot M, Pecquet C. Mining for JAK–STAT mutations in cancer. Trends Biochem Sci. 2008;33(3):122-131.
Crossref Google Scholar
13

Arora L, Kumar AP, Arfuso F, Chng WJ, Sethi G. The role of signal transducer and activator of transcription 3 (STAT3) and its targeted inhibition in hematological malignancies. Cancers (Basel). 2018;10(9):327.
Crossref Google Scholar
14

Wu Z, Liu J, Hu S, Zhu Y, Li S. Serine/threonine kinase 35, a target gene of STAT3, regulates the proliferation and apoptosis of osteosarcoma cells. Cell Physiol Biochem. 2018;45(2):808-818.
Crossref Google Scholar
15

Boudny M, Trbusek M. The important role of STAT3 in chronic lymphocytic leukaemia biology. Klin Onkol. 2020;33(1):32-38.
Crossref Google Scholar
16

Nairismägi M-, Gerritsen ME, Li ZM, et al. Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma. Leukemia. 2018;32(5):1147-1156.
Crossref Google Scholar
17

Thomas SJ, Snowden JA, Zeidler MP, Danson SJ. The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br J Cancer. 2015;113(3):365-371.
Crossref Google Scholar
18

Bose S, Banerjee S, Mondal A, et al. Targeting the JAK/STAT signaling pathway using phytocompounds for cancer prevention and therapy. Cells. 2020;9(6):1451.
Crossref Google Scholar
19

Benekli M, Baer MR, Baumann H, Wetzler M. Signal transducer and activator of transcription proteins in leukemias. Blood. 2003;101(8):2940-2954.
Crossref Google Scholar
20

Zheng Q, Dong H, Mo J, et al. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance. Theranostics. 2021;11(2):824-840.
Crossref Google Scholar
21

Li P, Grgurevic S, Liu Z, et al. Signal transducer and activator of transcription–3 induces microRNA-155 expression in chronic lymphocytic leukemia. PLoS One. 2013;8(6):e64678.
Crossref Google Scholar
22

Kuusanmäki H, Dufva O, Parri E, et al. Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling. Oncotarget. 2017;8(57):97516-97527.
Crossref Google Scholar
23

Furtek SL, Backos DS, Matheson CJ, Reigan P. Strategies and approaches of targeting STAT3 for cancer treatment. ACS Chem Biol. 2016;11(2):308-318.
Crossref Google Scholar
24

Zou S, Tong Q, Liu B, Huang W, Tian Y, Fu X. Targeting STAT3 in cancer immunotherapy. Mol Cancer. 2020;19(1):145.
Crossref Google Scholar
25

Cao Q, Li YY, He WF, et al. Interplay between microRNAs and the STAT3 signaling pathway in human cancers. Physiol Genomics. 2013;45(24):1206-1214.
Crossref Google Scholar
26

Shan D, Shang Y, Hu T. MicroRNA-411 inhibits cervical cancer progression by directly targeting STAT3. Oncol Res. 2019;27(3):349-358.
Crossref Google Scholar
27

Xu S, Zhao N, Hui L, Song M, Miao ZW, Jiang XJ. MicroRNA-124-3p inhibits the growth and metastasis of nasopharyngeal carcinoma cells by targeting STAT3. Oncol Rep. 2016;35(3):1385-1394.
Crossref Google Scholar
28

Tian K, Liu W, Zhang J, et al. MicroRNA-125b exerts antitumor functions in cutaneous squamous cell carcinoma by targeting the STAT3 pathway. Cell Mol Biol Lett. 2020;25:12.
Crossref Google Scholar
29

Cai K, Li HX, Li PP, Guo ZJ, Yang Y. MicroRNA-449b-3p inhibits epithelial-mesenchymal transition by targeting IL-6 and through the JAK2/STAT3 signaling pathway in non-small cell lung cancer. Exp Ther Med. 2020;19(4):2527-2534.
Crossref Google Scholar
30

Wang B, Hsu SH, Frankel W, Ghoshal K, Jacob ST. Stat3-mediated activation of microRNA-23a suppresses gluconeogenesis in hepatocellular carcinoma by down-regulating glucose-6-phosphatase and peroxisome proliferator-activated receptor gamma, coactivator 1 alpha. Hepatology. 2012;56(1):186-197.
Crossref Google Scholar
31

Tang Z, Xu T, Li Y, Fei W, Yang G, Hong Y. Inhibition of CRY2 by STAT3/miRNA-7-5p promotes osteoblast differentiation through upregulation of CLOCK/BMAL1/P300 expression. Mol Ther Nucleic Acids. 2020;19:865-876.
Crossref Google Scholar
32

Wang A, Deng S, Chen X, et al. miR-29a-5p/STAT3 positive feedback loop regulates TETs in colitis-associated colorectal cancer. Inflamm Bowel Dis. 2020;26(4):524-533.
Crossref Google Scholar
33

Cheng M, Wang B, Yang M, et al. microRNAs expression in relation to particulate matter exposure: a systematic review. Environ Pollut. 2020;260:113961.
Crossref Google Scholar
34

Azar MRMH, Akbari M, Mohammed HN, Asadi M, Mahdavi F. Dysregulation of miR-27a and SMAD2 can be a reliable indicator in the prognosis and diagnosis of CRC as well as in response to chemotherapy drugs. Gene Rep. 2020;21(3):100844.
Crossref Google Scholar
35

Azar MRMH, Aghazadeh H, Mohammed HN, et al. miR-193a-5p as a promising therapeutic candidate in colorectal cancer by reducing 5-FU and Oxaliplatin chemoresistance by targeting CXCR4. Int Immunopharmacol. 2021;92:107355.
Crossref Google Scholar
36

Liu D, Zhang N, Zhang X, Qin M, Dong Y, Jin L. MiR-410 down-regulates the expression of interleukin-10 by targeting STAT3 in the pathogenesis of systemic lupus erythematosus. Cell Physiol Biochem. 2016;39(1):303-315.
Crossref Google Scholar
37

Niu L, Yang W, Duan L, et al. Biological implications and clinical potential of metastasis-related miRNA in colorectal cancer. Mol Ther Nucleic Acids. 2020;23:42-54.
Crossref Google Scholar
38

He B, Zhao Z, Cai Q, et al. miRNA-based biomarkers, therapies, and resistance in cancer. Int J Biol Sci. 2020;16(14):2628-2647.
Crossref Google Scholar
39

Kabekkodu SP, Shukla V, Varghese VK, et al. Cluster miRNAs and cancer: diagnostic, prognostic and therapeutic opportunities. Wiley Interdiscip Rev RNA. 2020;11(2):e1563.
Crossref Google Scholar
40

Tamjidifar R, Akbari M, Tarzi S, et al. Prognostic and diagnostic values of miR-506 and SPON 1 in colorectal cancer with clinicopathological considerations. J Gastrointest Cancer. 2021;52(1):125-129.
Crossref Google Scholar
41

Rupaimoole R, Calin GA, Lopez-Berestein G, Sood AK. miRNA deregulation in cancer cells and the tumor microenvironment. Cancer Discov. 2016;6(3):235-246.
Crossref Google Scholar
42

Raza U, Zhang JD, Sahin O. MicroRNAs: master regulators of drug resistance, stemness, and metastasis. J Mol Med (Berl). 2014;92(4):321-336.
Crossref Google Scholar
43
NabipoorashrafiSAShomaliNSadat-HatamnezhadLmiR-143 acts as an inhibitor of migration and proliferation as well as an inducer of apoptosis in melanoma cancer cells in vitroIUBMB Life20207292034204410.1002/iub.2345

Nabipoorashrafi SA, Shomali N, Sadat-Hatamnezhad L, et al. miR-143 acts as an inhibitor of migration and proliferation as well as an inducer of apoptosis in melanoma cancer cells in vitro. IUBMB Life. 2020;72(9):2034-2044.
Crossref Google Scholar
44

Samidurai A, Roh SK, Prakash M, et al. STAT3-miR-17/20 signalling axis plays a critical role in attenuating myocardial infarction following rapamycin treatment in diabetic mice. Cardiovasc Res. 2020;116(13):2103-2115.
Crossref Google Scholar
45

Dong L, Cao X, Luo Y, Zhang G, Zhang D. A positive feedback loop of lncRNA DSCR8/miR-98-5p/STAT3/HIF-1α plays a role in the progression of ovarian cancer. Front Oncol. 2020;10:1713.
Crossref Google Scholar
46

Li Z, Song Y, He T, et al. M2 microglial small extracellular vesicles reduce glial scar formation via the miR-124/STAT3 pathway after ischemic stroke in mice. Theranostics. 2021;11(3):1232-1248.
Crossref Google Scholar
47

Yan X, Zeng D, Zhu H, et al. MiRNA-532-5p regulates CUMS-induced depression-like behaviors and modulates LPS-induced proinflammatory cytokine signaling by targeting STAT3. Neuropsychiatr Dis Treat. 2020;16:2753-2764.
Crossref Google Scholar
48

Chen N, Feng L, Qu H, et al. Overexpression of IL-9 induced by STAT3 phosphorylation is mediated by miR-155 and miR-21 in chronic lymphocytic leukemia. Oncol Rep. 2018;39(6):3064-3072.
Crossref Google Scholar
49

Carabia J, Carpio C, Abrisqueta P, et al. Microenvironment regulates the expression of miR-21 and tumor suppressor genes PTEN, PIAS3 and PDCD4 through ZAP-70 in chronic lymphocytic leukemia. Sci Rep. 2017;7(1):12262.
Crossref Google Scholar
50

Soroosh P, Doherty TA. Th9 and allergic disease. Immunology. 2009;127(4):450-458.
Crossref Google Scholar
51

Tete S, Saggini A, Maccauro G, et al. Interleukin-9 and mast cells. J Biol Regul Homeost Agents. 2012;26(3):319-326.
Google Scholar
52

Hornakova T, Staerk J, Royer Y, et al. Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers. J Biol Chem. 2009;284(11):6773-6781.
Crossref Google Scholar
53

Carretero R, Wang E, Rodriguez AI, et al. Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int J Cancer. 2012;131(2):387-395.
Crossref Google Scholar
54

Randhawa J, Ostojic A, Vrhovac R, Atallah E, Verstovsek S. Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors. J Hematol Oncol. 2012;5:43.
Crossref Google Scholar
55

Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497-2506.
Crossref Google Scholar
56

Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005;353(17):1793-1801.
Crossref Google Scholar
57

Saleh LM, Wang W, Herman SE, et al. Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia. Leukemia. 2017;31(2):340-349.
Crossref Google Scholar
58

Rossi S, Shimizu M, Barbarotto E, et al. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood. 2010;116(6):945-952.
Crossref Google Scholar
59

Fu X, Han Y, Wu Y, et al. Prognostic role of microRNA-21 in various carcinomas: a systematic review and meta-analysis. Eur J Clin Invest. 2011;41(11):1245-1253.
Crossref Google Scholar
60

Jazbutyte V, Thum T. MicroRNA-21: from cancer to cardiovascular disease. Curr Drug Targets. 2010;11(8):926-935.
Crossref Google Scholar
61

Xiong Q, Zhong Q, Zhang J, et al. Identification of novel miR-21 target proteins in multiple myeloma cells by quantitative proteomics. J Proteome Res. 2012;11(4):2078-2090.
Crossref Google Scholar
62

Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem. 2008;283(2):1026-1033.
Crossref Google Scholar
63

Wickramasinghe NS, Manavalan TT, Dougherty SM, Riggs KA, Li Y, Klinge CM. Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. Nucleic Acids Res. 2009;37(8):2584-2595.
Crossref Google Scholar
64

Löffler D, Brocke-Heidrich K, Pfeifer G, et al. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood. 2007;110(4):1330-1333.
Crossref Google Scholar
65

Leng RX, Pan HF, Qin WZ, Chen GM, Ye DQ. Role of microRNA-155 in autoimmunity. Cytokine Growth Factor Rev. 2011;22(3):141-147.
Crossref Google Scholar
66

Costinean S, Zanesi N, Pekarsky Y, et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A. 2006;103(18):7024-7029.
Crossref Google Scholar
67

Thai TH, Calado DP, Casola S, et al. Regulation of the germinal center response by microRNA-155. Science. 2007;316(5824):604-608.
Crossref Google Scholar
68

Haasch D, Chen YW, Reilly RM, et al. T cell activation induces a noncoding RNA transcript sensitive to inhibition by immunosuppressant drugs and encoded by the proto-oncogene, BIC. Cell Immunol. 2002;217(1–2):78-86.
Crossref Google Scholar
69

Eis PS, Tam W, Sun L, et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A. 2005;102(10):3627-3632.
Crossref Google Scholar
70

Fulci V, Chiaretti S, Goldoni M, et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood. 2007;109(11):4944-4951.
Crossref Google Scholar
71

Kluiver J, Poppema S, de Jong D, et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol. 2005;207(2):243-249.
Crossref Google Scholar
72

Metzler M, Wilda M, Busch K, Viehmann S, Borkhardt A. High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma. Genes Chromosomes Cancer. 2004;39(2):167-169.
Crossref Google Scholar
73

Hazan-Halevy I, Harris D, Liu Z, et al. STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood. 2010;115(14):2852-2863.
Crossref Google Scholar
74

Li P, Harris D, Liu Z, Liu J, Keating M, Estrov Z. Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells. PLoS One. 2010;5(7):e11859.
Crossref Google Scholar
75
TivnanATraceyLBuckleyPGAlcockLCDavidoffAMStallingsRLMicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastomaBMC Cancer2011113310.1186/1471-2407-11-33

Tivnan A, Tracey L, Buckley PG, Alcock LC, Davidoff AM, Stallings RL. MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma. BMC Cancer. 2011;11:33.
Crossref Google Scholar
76

Vargova K, Curik N, Burda P, et al. MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia. Blood. 2011;117(14):3816-3825.
Crossref Google Scholar
77

Aaronson DS, Horvath CM. A road map for those who don't know JAK-STAT. Science. 2002;296(5573):1653-1655.
Crossref Google Scholar
78

Marinescu C, Vlădăreanu AM, Mihai F. Acute lymphocytic leukemia in adults. Pathologic features and prognosis. Rom J Intern Med. 2015;53(1):31-36.
Crossref Google Scholar
79

Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10(2):125-134.
Crossref Google Scholar
80

Igwe IJ, Yang D, Merchant A, et al. The presence of Philadelphia chromosome does not confer poor prognosis in adult pre-B acute lymphoblastic leukaemia in the tyrosine kinase inhibitor era – a surveillance, epidemiology, and end results database analysis. Br J Haematol. 2017;179(4):618-626.
Crossref Google Scholar
81

Möricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111(9):4477-4489.
Crossref Google Scholar
82

Reynaud D, Pietras E, Barry-Holson K, et al. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell. 2011;20(5):661-673.
Crossref Google Scholar
83

Jiang T, Chen J, Huang XB, Li YX, Zhong L. miR-451a induced apoptosis of Philadelphia chromosome-positive acute lymphoblastic leukemia cells by targeting IL-6R. Neoplasma. 2018;65(6):907-914.
Crossref Google Scholar
84

Wang SW, Sun YM. The IL-6/JAK/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (Review). Int J Oncol. 2014;44(4):1032-1040.
Crossref Google Scholar
85

Garbers C, Aparicio-Siegmund S, Rose-John S. The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition. Curr Opin Immunol. 2015;34:75-82.
Crossref Google Scholar
86

Soltani I, Douzi K, Gharbi H, et al. Downregulation of miR-451 in Tunisian chronic myeloid leukemia patients: potential implication in imatinib resistance. Hematology. 2017;22(4):201-207.
Crossref Google Scholar
87

Chen Q, Hu H, Jiao D, et al. miR-126-3p and miR-451a correlate with clinicopathological features of lung adenocarcinoma: the underlying molecular mechanisms. Oncol Rep. 2016;36(2):909-917.
Crossref Google Scholar
88

Su Z, Ni L, Yu W, et al. MicroRNA-451a is associated with cell proliferation, migration and apoptosis in renal cell carcinoma. Mol Med Rep. 2015;11(3):2248-2254.
Crossref Google Scholar
89

Lopotová T, Žáčková M, Klamová H, Moravcová J. MicroRNA-451 in chronic myeloid leukemia: miR-451–BCR-ABL regulatory loop? Leuk Res. 2011;35(7):974-977.
Crossref Google Scholar
90

Lamy T, Moignet A, Loughran Jr TP. LGL leukemia: from pathogenesis to treatment. Blood. 2017;129(9):1082-1094.
Crossref Google Scholar
91

Semenzato G, Zambello R, Starkebaum G, Oshimi K, Loughran Jr TP. The lymphoproliferative disease of granular lymphocytes: updated criteria for diagnosis. Blood. 1997;89(1):256-260.
Crossref Google Scholar
92

Mariotti B, Calabretto G, Rossato M, et al. Identification of a miR-146b-Fas ligand axis in the development of neutropenia in T large granular lymphocyte leukemia. Haematologica. 2020;105(5):1351-1360.
Crossref Google Scholar
93

Leblanc F, Zhang D, Liu X, Loughran TP. Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets. Future Oncol. 2012;8(7):787-801.
Crossref Google Scholar
94

Epling-Burnette PK, Zhong B, Bai F, et al. Cooperative regulation of Mcl-1 by Janus kinase/stat and phosphatidylinositol 3-kinase contribute to granulocyte-macrophage colony-stimulating factor-delayed apoptosis in human neutrophils. J Immunol. 2001;166(12):7486-7495.
Crossref Google Scholar
95

Teramo A, Barilà G, Calabretto G, et al. STAT3 mutation impacts biological and clinical features of T-LGL leukemia. Oncotarget. 2017;8(37):61876-61889.
Crossref Google Scholar
96

Tanaka M, Suda T, Haze K, et al. Fas ligand in human serum. Nat Med. 1996;2(3):317-322.
Crossref Google Scholar
97

Saitoh T, Karasawa M, Sakuraya M, et al. Improvement of extrathymic T cell type of large granular lymphocyte (LGL) leukemia by cyclosporin A: the serum level of Fas ligand is a marker of LGL leukemia activity. Eur J Haematol. 2000;65(4):272-275.
Crossref Google Scholar
98

Liu JH, Wei S, Lamy T, et al. Chronic neutropenia mediated by fas ligand. Blood. 2000;95(10):3219-3222.
Crossref Google Scholar
99

Perzova R, Loughran Jr TP. Constitutive expression of Fas ligand in large granular lymphocyte leukaemia. Br J Haematol. 1997;97(1):123-126.
Crossref Google Scholar
100

Jerez A, Clemente MJ, Makishima H, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 2012;120(15):3048-3057.
Crossref Google Scholar
101

Koskela HL, Eldfors S, Ellonen P, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012;366(20):1905-1913.
Crossref Google Scholar
102

Lee H, Deng J, Xin H, Liu Y, Pardoll D, Yu H. A requirement of STAT3 DNA binding precludes Th-1 immunostimulatory gene expression by NF-κB in tumors. Cancer Res. 2011;71(11):3772-3780.
Crossref Google Scholar
103

Niu G, Wright KL, Ma Y, et al. Role of Stat3 in regulating p53 expression and function. Mol Cell Biol. 2005;25(17):7432-7440.
Crossref Google Scholar
104

Xiang M, Birkbak NJ, Vafaizadeh V, et al. STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-κB to IL-6 signaling axis and STAT3-driven cancer phenotypes. Sci Signal. 2014;7(310):ra11.
Crossref Google Scholar
105

Villela D, Ramalho RF, Silva AR, et al. Differential DNA methylation of microRNA genes in temporal cortex from Alzheimer's disease individuals. Neural Plast. 2016;2016:2584940.
Crossref Google Scholar
106

Curtale G, Mirolo M, Renzi TA, Rossato M, Bazzoni F, Locati M. Negative regulation of Toll-like receptor 4 signaling by IL-10–dependent microRNA-146b. Proc Natl Acad Sci U S A. 2013;110(28):11499-11504.
Crossref Google Scholar
107

Renzi TA, Rubino M, Gornati L, Garlanda C, Locati M, Curtale G. MiR-146b mediates endotoxin tolerance in human phagocytes. Mediators Inflamm. 2015;2015:145305.
Crossref Google Scholar
108

Cheng HS, Sivachandran N, Lau A, et al. Micro RNA-146 represses endothelial activation by inhibiting pro-inflammatory pathways. EMBO Mol Med. 2013;5(7):1017-1034.
Crossref Google Scholar
109

Drury GL, Di Marco S, Dormoy-Raclet V, Desbarats J, Gallouzi IE. FasL expression in activated T lymphocytes involves HuR-mediated stabilization. J Biol Chem. 2010;285(41):31130-31138.
Crossref Google Scholar
110

Yang W, Yu H, Shen Y, Liu Y, Yang Z, Sun T. MiR-146b-5p overexpression attenuates stemness and radioresistance of glioma stem cells by targeting HuR/lincRNA-p21/β-catenin pathway. Oncotarget. 2016;7(27):41505-41526.
Crossref Google Scholar
111

Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol. 2014;89(5):547-556.
Crossref Google Scholar
112

Zhang Y, Zhang HE, Liu Z. MicroRNA-147 suppresses proliferation, invasion and migration through the AKT/mTOR signaling pathway in breast cancer. Oncol Lett. 2016;11(1):405-410.
Crossref Google Scholar
113

Sui CJ, Xu F, Shen WF, et al. MicroRNA-147 suppresses human hepatocellular carcinoma proliferation migration and chemosensitivity by inhibiting HOXC6. Am J Cancer Res. 2016;6(12):2787-2798.
Google Scholar
114

Lee CG, McCarthy S, Gruidl M, Timme C, Yeatman TJ. MicroRNA-147 induces a mesenchymal-to-epithelial transition (MET) and reverses EGFR inhibitor resistance. PLoS One. 2014;9(1):e84597.
Crossref Google Scholar
115

Chu G, Zhang J, Chen X. Serum level of microRNA-147 as diagnostic biomarker in human non-small cell lung cancer. J Drug Target. 2016;24(7):613-617.
Crossref Google Scholar
116

Yao Y, Suo AL, Li ZF, et al. MicroRNA profiling of human gastric cancer. Mol Med Rep. 2009;2(6):963-970.
Google Scholar
117

Han L, Dong Z, Liu N, Xie F, Wang N. Maternally expressed gene 3 (MEG3) enhances PC12 cell hypoxia injury by targeting MiR-147. Cell Physiol Biochem. 2017;43(6):2457-2469.
Crossref Google Scholar
118

Li ZY, Yang L, Liu XJ, Wang XZ, Pan YX, Luo JM. The long noncoding RNA MEG3 and its target miR-147 regulate JAK/STAT pathway in advanced chronic myeloid leukemia. EBioMedicine. 2018;34:61-75.
Crossref Google Scholar
119

Tatarano S, Chiyomaru T, Kawakami K, et al. Novel oncogenic function of mesoderm development candidate 1 and its regulation by MiR-574-3p in bladder cancer cell lines. Int J Oncol. 2012;40(4):951-959.
Crossref Google Scholar
120

Krishnan P, Ghosh S, Wang B, et al. Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer. BMC Genomics. 2015;16(1):735.
Crossref Google Scholar
121

Su Y, Ni Z, Wang G, et al. Aberrant expression of microRNAs in gastric cancer and biological significance of miR-574-3p. Int Immunopharmacol. 2012;13(4):468-475.
Crossref Google Scholar
122

Xu H, Liu X, Zhou J, Chen X, Zhao J. miR-574-3p acts as a tumor promoter in osteosarcoma by targeting SMAD4 signaling pathway. Oncol Lett. 2016;12(6):5247-5253.
Crossref Google Scholar
123

Okumura T, Kojima H, Miwa T, et al. The expression of microRNA 574-3p as a predictor of postoperative outcome in patients with esophageal squamous cell carcinoma. World J Surg Oncol. 2016;14(1):228.
Crossref Google Scholar
124

Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer. 2007;110(9):1911-1928.
Crossref Google Scholar
125

Maeda K, Baba Y, Nagai Y, et al. IL-6 blocks a discrete early step in lymphopoiesis. Blood. 2005;106(3):879-885.
Crossref Google Scholar
126

Ciarcia R, Vitiello MT, Galdiero M, et al. Imatinib treatment inhibit IL-6, IL-8, NF-KB and AP-1 production and modulate intracellular calcium in CML patients. J Cell Physiol. 2012;227(6):2798-2803.
Crossref Google Scholar
127

Yang H, Zhang J, Li J, et al. Overexpression of miR-574-3p suppresses proliferation and induces apoptosis of chronic myeloid leukemia cells via targeting IL6/JAK/STAT3 pathway. Exp Ther Med. 2018;16(5):4296-4302.
Crossref Google Scholar
128

Piel FB, Patil AP, Howes RE, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet. 2013;381(9861):142-151.
Crossref Google Scholar
129

Dong M, McGann PT. Changing the clinical paradigm of hydroxyurea treatment for sickle cell anemia through precision medicine. Clin Pharmacol Ther. 2021;109(1):73-81.
Crossref Google Scholar
130

Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639-1644.
Crossref Google Scholar
131

Ward CM, Li B, Pace BS. Original Research: Stable expression of miR-34a mediates fetal hemoglobin induction in K562 cells. Exp Biol Med (Maywood). 2016;241(7):719-729.
Crossref Google Scholar
132

Poillon WN, Kim BC, Rodgers GP, Noguchi CT, Schechter AN. Sparing effect of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S at physiologic ligand saturations. Proc Natl Acad Sci U S A. 1993;90(11):5039-5043.
Crossref Google Scholar
133

Vekilov PG. Sickle-cell haemoglobin polymerization: is it the primary pathogenic event of sickle-cell anaemia? Br J Haematol. 2007;139(2):173-184.
Crossref Google Scholar
134

Weng W, Wang M, Xie S, et al. YY1-C/EBPα-miR34a regulatory circuitry is involved in renal cell carcinoma progression. Oncol Rep. 2014;31(4):1921-1927.
Crossref Google Scholar
135

Chen QR, Yu LR, Tsang P, et al. Systematic proteome analysis identifies transcription factor YY1 as a direct target of miR-34a. J Proteome Res. 2011;10(2):479-487.
Crossref Google Scholar
136

Zhao J, Lammers P, Torrance CJ, Bader AG. TP53-independent function of miR-34a via HDAC1 and p21(CIP1/WAF1.). Mol Ther. 2013;21(9):1678-1686.
Crossref Google Scholar
137

Lal A, Thomas MP, Altschuler G, et al. Capture of microRNA–bound mRNAs identifies the tumor suppressor miR-34a as a regulator of growth factor signaling. PLoS Genet. 2011;7(11):e1002363.
Crossref Google Scholar
138

Yao X, Kodeboyina S, Liu L, et al. Role of STAT3 and GATA-1 interactions in gamma-globin gene expression. Exp Hematol. 2009;37(8):889-900.
Crossref Google Scholar
139

Wierenga AT, Vogelzang I, Eggen BJ, Vellenga E. Erythropoietin-induced serine 727 phosphorylation of STAT3 in erythroid cells is mediated by a MEK-, ERK-, and MSK1-dependent pathway. Exp Hematol. 2003;31(5):398-405.
Crossref Google Scholar
140

De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6(7):e441.
Crossref Google Scholar
141

Hitchcock IS, Kaushansky K. Thrombopoietin from beginning to end. Br J Haematol. 2014;165(2):259-268.
Crossref Google Scholar
142

Drachman JG, Sabath DF, Fox NE, Kaushansky K. Thrombopoietin signal transduction in purified murine megakaryocytes. Blood. 1997;89(2):483-492.
Crossref Google Scholar
143

Norfo R, Zini R, Pennucci V, et al. miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis. Blood. 2014;124(13):e21-e32.
Crossref Google Scholar
144

Rontauroli S, Norfo R, Pennucci V, et al. miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6. Oncotarget. 2017;8(13):21380-21397.
Crossref Google Scholar
145

Shen R, Wang Y, Wang CX, et al. MiRNA-155 mediates TAM resistance by modulating SOCS6-STAT3 signalling pathway in breast cancer. Am J Transl Res. 2015;7(10):2115-2126.
Google Scholar
146

Hwang MN, Min CH, Kim HS, et al. The nuclear localization of SOCS6 requires the N-terminal region and negatively regulates Stat3 protein levels. Biochem Biophys Res Commun. 2007;360(2):333-338.
Crossref Google Scholar
147

Goldberg SL, Noel P, Klumpp TR, Dewald GW. The erythroid leukemias: a comparative study of erythroleukemia (FAB M6) and Di Guglielmo disease. Am J Clin Oncol. 1998;21(1):42-47.
Crossref Google Scholar
148

Wells AW, Bown N, Reid MM, Hamilton PJ, Jackson GH, Taylor PR. Erythroleukaemia in the north of England: a population based study. J Clin Pathol. 2001;54(8):608-612.
Crossref Google Scholar
149

Hasserjian RP, Zuo Z, Garcia C, et al. Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. Blood. 2010;115(10):1985-1992.
Crossref Google Scholar
150

Santos FP, Faderl S, Garcia-Manero G, et al. Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution. Leukemia. 2009;23(12):2275-2280.
Crossref Google Scholar
151

Hegde S, Ni S, He S, et al. Stat3 promotes the development of erythroleukemia by inducing Pu. 1 expression and inhibiting erythroid differentiation. Oncogene. 2009;28(38):3349-3359.
Crossref Google Scholar
152

Su R, Dong L, Zou D, et al. microRNA-23a,-27a and-24 synergistically regulate JAK1/Stat3 cascade and serve as novel therapeutic targets in human acute erythroid leukemia. Oncogene. 2016;35(46):6001-6014.
Crossref Google Scholar
153

Zhao J, Xu Y, Zong Y, et al. Inhibition of Stat3 expression induces apoptosis and suppresses proliferation in human leukemia HL-60 cells. Hematology. 2011;16(4):232-235.
Crossref Google Scholar
154

Epling-Burnette PK, Liu JH, Catlett-Falcone R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest. 2001;107(3):351-362.
Crossref Google Scholar
155

Xu S, Xu Z, Liu B, et al. LIFRα-CT3 induces differentiation of a human acute myelogenous leukemia cell line HL-60 by suppressing miR-155 expression through the JAK/STAT pathway. Leuk Res. 2014;38(10):1237-1244.
Crossref Google Scholar
156

Guo SY, Shen X, Yang J, et al. TIMP-1 mediates the inhibitory effect of interleukin-6 on the proliferation of a hepatocarcinoma cell line in a STAT3-dependent manner. Braz J Med Biol Res. 2007;40(5):621-631.
Crossref Google Scholar
157

Ying J, Tsujii M, Kondo J, et al. The effectiveness of an anti-human IL-6 receptor monoclonal antibody combined with chemotherapy to target colon cancer stem-like cells. Int J Oncol. 2015;46(4):1551-1559.
Crossref Google Scholar
158

Cheng X, Jin G, Zhang X, Tian M, Zou L. Stage-dependent STAT3 activation is involved in the differentiation of rat hippocampus neural stem cells. Neurosci Lett. 2011;493(1–2):18-23.
Crossref Google Scholar
159

Steyn PJ, Dzobo K, Smith RI, Myburgh KH. Interleukin-6 induces myogenic differentiation via JAK2-STAT3 signaling in mouse C2C12 myoblast cell line and primary human myoblasts. Int J Mol Sci. 2019;20(21):5273.
Crossref Google Scholar
160

Nakajima K, Yamanaka Y, Nakae K, et al. A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J. 1996;15(14):3651-3658.
Crossref Google Scholar
161

Chonov DC, Ignatova MMK, Ananiev JR, Gulubova MV. IL-6 activities in the tumour microenvironment. Part 1. Open Access Maced J Med Sci. 2019;7(14):2391-2398.
Crossref Google Scholar
162

Taga T, Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol. 1997;15:797-819.
Crossref Google Scholar
163

Sun Q, Wang J, Xiong J, Yang L, Liu H. Free LIF receptor α-chain distal cytoplasmic motifs enhance Jak2-independent STAT3 phosphorylation and induce differentiation in HL-60 cells. Oncol Rep. 2011;26(2):399-404.
Google Scholar
164

Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol. 2002;12(9):735-739.
Crossref Google Scholar
165

Jongen-Lavrencic M, Sun SM, Dijkstra MK, Valk PJ, Löwenberg B. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood. 2008;111(10):5078-5085.
Crossref Google Scholar
166

Marcucci G, Mrózek K, Radmacher MD, Garzon R, Bloomfield CD. The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood. 2011;117(4):1121-1129.
Crossref Google Scholar
167

Garzon R, Volinia S, Liu CG, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood. 2008;111(6):3183-3189.
Crossref Google Scholar
168

McCoy CE, Sheedy FJ, Qualls JE, et al. IL-10 inhibits miR-155 induction by toll-like receptors. J Biol Chem. 2010;285(27):20492-20498.
Crossref Google Scholar
169

Starr R, Willson TA, Viney EM, et al. A family of cytokine-inducible inhibitors of signalling. Nature. 1997;387(6636):917-921.
Crossref Google Scholar
170

Semenza GL. Oxygen sensing, homeostasis, and disease. N Engl J Med. 2011;365(6):537-547.
Crossref Google Scholar
171

Marofi F, Shomali N, Younus LA, et al. Under hypoxic conditions, MSCs affect the expression and methylation level of survival-related genes in ALL independent of apoptosis pathways in vitro. Biotechnol Appl Biochem; 2021. https://doi.org/10.1002/bab.2154.
Crossref Google Scholar
172

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
Crossref Google Scholar
173

Huang Y, Du KM, Xue ZH, et al. Cobalt chloride and low oxygen tension trigger differentiation of acute myeloid leukemic cells: possible mediation of hypoxia-inducible factor-1alpha. Leukemia. 2003;17(11):2065-2073.
Crossref Google Scholar
174

Zhao XY, Zhao KW, Jiang Y, Zhao M, Chen GQ. Synergistic induction of galectin-1 by CCAAT/enhancer binding protein α and hypoxia-inducible factor 1α and its role in differentiation of acute myeloid leukemic cells. J Biol Chem. 2011;286(42):36808-36819.
Crossref Google Scholar
175

He M, Wang QY, Yin QQ, et al. HIF-1α downregulates miR-17/20a directly targeting p21 and STAT3: a role in myeloid leukemic cell differentiation. Cell Death Differ. 2013;20(3):408-418.
Crossref Google Scholar
176

Kim JS, Cho EW, Chung HW, Kim IG. Effects of Tiron, 4, 5-dihydroxy-1, 3-benzene disulfonic acid, on human promyelotic HL-60 leukemia cell differentiation and death. Toxicology. 2006;223(1–2):36-45.
Crossref Google Scholar
177

Liu W, Guo M, Xu YB, et al. Induction of tumor arrest and differentiation with prolonged survival by intermittent hypoxia in a mouse model of acute myeloid leukemia. Blood. 2006;107(2):698-707.
Crossref Google Scholar
178

Nguyen-Khac F, Della Valle V, Lopez RG, et al. Functional analyses of the TEL-ARNT fusion protein underscores a role for oxygen tension in hematopoietic cellular differentiation. Oncogene. 2006;25(35):4840-4847.
Crossref Google Scholar
179

Song LP, Zhang J, Wu SF, et al. Hypoxia-inducible factor-1alpha-induced differentiation of myeloid leukemic cells is its transcriptional activity independent. Oncogene. 2008;27(4):519-527.
Crossref Google Scholar
180

Hayashita Y, Osada H, Tatematsu Y, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 2005;65(21):9628-9632.
Crossref Google Scholar
181

He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature. 2005;435(7043):828-833.
Crossref Google Scholar
182

Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103(7):2257-2261.
Crossref Google Scholar
183

Taguchi A, Yanagisawa K, Tanaka M, et al. Identification of hypoxia-inducible factor-1α as a novel target for miR-17-92 microRNA cluster. Cancer Res. 2008;68(14):5540-5545.
Crossref Google Scholar
184

Ghosh G, Subramanian IV, Adhikari N, et al. Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF-α isoforms and promotes angiogenesis. J Clin Invest. 2010;120(11):4141-4154.
Crossref Google Scholar
185

Cascio S, D'Andrea A, Ferla R, et al. miR-20b modulates VEGF expression by targeting HIF-1α and STAT3 in MCF-7 breast cancer cells. J Cell Physiol. 2010;224(1):242-249.
Crossref Google Scholar
186

Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009;9(6):400-414.
Crossref Google Scholar
187

Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol. 2007;178(5):2623-2629.
Crossref Google Scholar
188

Xie W, Hu S, Xu J, Chen Z, Medeiros LJ, Tang G. Acute myeloid leukemia with t (8; 16)(p11. 2; p13. 3)/KAT6A-CREBBP in adults. Ann Hematol. 2019;98(5):1149-1157.
Crossref Google Scholar
189

Díaz-Beyá M, Navarro A, Ferrer G, et al. Acute myeloid leukemia with translocation (8; 16)(p11; p13) and MYST3-CREBBP rearrangement harbors a distinctive microRNA signature targeting RET proto-oncogene. Leukemia. 2013;27(3):595-603.
Crossref Google Scholar
190

Park GB, Kim D. MicroRNA-503-5p inhibits the CD97-mediated JAK2/STAT3 pathway in metastatic or paclitaxel-resistant ovarian cancer cells. Neoplasia. 2019;21(2):206-215.
Crossref Google Scholar
191

Yu, Wu D, Gao H, et al. Clinical utility of a STAT3-regulated miRNA-200 family signature with prognostic potential in early gastric cancer. Clin Cancer Res. 2018;24(6):1459-1472.
Crossref Google Scholar
192

Chen MW, Yang ST, Chien MH, et al. The STAT3-miRNA-92-Wnt signaling pathway regulates spheroid formation and malignant progression in ovarian cancer. Cancer Res. 2017;77(8):1955-1967.
Crossref Google Scholar
193

Rokavec M, Öner MG, Li H, et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Investig. 2014;124(4):1853-1867.
Crossref Google Scholar
194

Hu H, Zhang Q, Chen W, et al. MicroRNA-301a promotes pancreatic cancer invasion and metastasis through the JAK/STAT3 signaling pathway by targeting SOCS5. J Carcinog. 2020;41(4):502-514.
Crossref Google Scholar
195

Wang X, Qiu W, Zhang G, et al. MicroRNA-204 targets JAK2 in breast cancer and induces cell apoptosis through the STAT3/BCl-2/survivin pathway. Int J Clin Exp Pathol. 2015;8(5):5017-5025.
Google Scholar
196

Zhou W, Bi X, Gao G, Sun L. miRNA-133b and miRNA-135a induce apoptosis via the JAK2/STAT3 signaling pathway in human renal carcinoma cells. Biomed Pharmacother. 2016;84:722-729.
Crossref Google Scholar
197

Patel K, Kollory A, Takashima A, Sarkar S, Faller DV, Ghosh SKJCl. MicroRNA let-7 downregulates STAT3 phosphorylation in pancreatic cancer cells by increasing SOCS3 expression. Cancer Lett. 2014;347(1):54-64.
Crossref Google Scholar
198

Zhang Y, Li X, Zhang J, Liang H. Natural killer T cell cytotoxic activity in cervical cancer is facilitated by the LINC00240/microRNA-124-3p/STAT3/MICA axis. Cancer Lett. 2020;474:63-73.
Crossref Google Scholar
199

Haghikia A, Hoch M, Stapel B, Hilfiker-Kleiner D. STAT3 regulation of and by microRNAs in development and disease. JAKSTAT. 2012;1(3):143-150.
Crossref Google Scholar
200

El-Daly SM, Omara EA, Hussein J, Youness ER, El-Khayat ZJM. Differential expression of miRNAs regulating NF-κB and STAT3 crosstalk during colitis-associated tumorigenesis. Mol Cell Probes. 2019;47:101442.
Crossref Google Scholar
201

Xue D, Yang Y, Liu Y, et al. MicroRNA-206 attenuates the growth and angiogenesis in non-small cell lung cancer cells by blocking the 14-3-3ζ/STAT3/HIF-1α/VEGF signaling. Oncotarget. 2016;7(48):79805-79813.
Crossref Google Scholar
202

Wei R, Yang Q, Han B, et al. microRNA-375 inhibits colorectal cancer cells proliferation by downregulating JAK2/STAT3 and MAP3K8/ERK signaling pathways. Oncotarget. 2017;8(10):16633-16641.
Crossref Google Scholar
203

Tao Y, Yang S, Wu Y, et al. MicroRNA-216a inhibits the metastasis of gastric cancer cells by targeting JAK2/STAT3-mediated EMT process. Oncotarget. 2017;8(51):88870-88881.
Crossref Google Scholar
204

Xu Y, Han YF, Zhu SJ, Dong JD, Ye B. miRNA-148a inhibits cell growth of papillary thyroid cancer through STAT3 and PI3K/AKT signaling pathways. Oncol Rep. 2017;38(5):3085-3093.
Crossref Google Scholar
205

Yang Y, Ding L, Hu Q, et al. MicroRNA-218 functions as a tumor suppressor in lung cancer by targeting IL-6/STAT3 and negatively correlates with poor prognosis. Mol Cancer. 2017;16(1):1-13.
Crossref Google Scholar
206

Mariotti B, Calabretto G, Rossato M, et al. Identification of a miR-146b-FasL axis in the development of neutropenia in T large granular lymphocyte leukemia. Haematologica. 2019;49:90.
Crossref Google Scholar
Genes & Diseases
Volume 9 Issue 4,
July 2022
Pages 849-867
DOI: 10.1016/j.gendis.2021.10.009
Cite this article:
Sajjadi-Dokht M, Merza Mohamad TA, Sulaiman Rahman H, et al. MicroRNAs and JAK/STAT3 signaling: A new promising therapeutic axis in blood cancers. Genes & Diseases, 2022, 9(4): 849-867. https://doi.org/10.1016/j.gendis.2021.10.009

362

Views

9

Downloads

13

Crossref

14

Web of Science

16

Scopus

2

CSCD

Altmetrics
Received: 30 April 2021
Revised: 16 September 2021
Accepted: 22 October 2021
Published: 03 December 2021
© 2021, Chongqing Medical University.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Return